These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9719457)

  • 21. Functional analysis of P-glycoprotein and multidrug resistance associated protein related multidrug resistance in AML-blasts.
    Brügger D; Herbart H; Gekeler V; Seitz G; Liu C; Klingebiel T; Orlikowsky T; Einsele H; Denzlinger C; Bader P; Niethammer D; Beck JF
    Leuk Res; 1999 May; 23(5):467-75. PubMed ID: 10374860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia.
    Raaijmakers MH; de Grouw EP; van der Reijden BA; de Witte TJ; Jansen JH; Raymakers RA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3452-8. PubMed ID: 16740770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-cell image analysis to assess ABC-transporter-mediated efflux in highly purified hematopoietic progenitors.
    Raaijmakers HG; Van Den Bosch G; Boezeman J; De Witte T; Raymakers RA
    Cytometry; 2002 Dec; 49(4):135-42. PubMed ID: 12454976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular identification and functional characterization of Mdr1a in rat cholangiocytes.
    Gigliozzi A; Fraioli F; Sundaram P; Lee J; Mennone A; Alvaro D; Boyer JL
    Gastroenterology; 2000 Oct; 119(4):1113-22. PubMed ID: 11040198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs.
    Klimecki WT; Taylor CW; Dalton WS
    J Clin Immunol; 1995 May; 15(3):152-8. PubMed ID: 7559918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
    Ahmed-Belkacem A; Pozza A; Muñoz-Martínez F; Bates SE; Castanys S; Gamarro F; Di Pietro A; Pérez-Victoria JM
    Cancer Res; 2005 Jun; 65(11):4852-60. PubMed ID: 15930306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway.
    Pallis M; Russell N
    Blood; 2000 May; 95(9):2897-904. PubMed ID: 10779437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents.
    Quesada AR; Barbacid MM; Mira E; Aracil M; Márquez G
    Cancer Lett; 1996 Jan; 99(1):109-14. PubMed ID: 8564921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine.
    Hofmann J; Wolf A; Spitaler M; Böck G; Drach J; Ludescher C; Grunicke H
    J Cancer Res Clin Oncol; 1992; 118(5):361-6. PubMed ID: 1349891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers.
    Pilarski LM; Yatscoff RW; Murphy GF; Belch AR
    Leukemia; 1998 Apr; 12(4):505-9. PubMed ID: 9557608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts.
    Pallis M; Turzanski J; Langabeer S; Russell NH
    Adv Exp Med Biol; 1999; 457():77-88. PubMed ID: 10500783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
    Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
    Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.
    Gekeler V; Boer R; Uberall F; Ise W; Schubert C; Utz I; Hofmann J; Sanders KH; Schächtele C; Klemm K; Grunicke H
    Br J Cancer; 1996 Sep; 74(6):897-905. PubMed ID: 8826855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro.
    Haberl I; Swatonek H; Schaufler K; Ulsperger E; Wenzl E; Theyer G; Hamilton G; Thalhammer T
    Int J Oncol; 1998 May; 12(5):1137-42. PubMed ID: 9538140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.
    Witherspoon SM; Emerson DL; Kerr BM; Lloyd TL; Dalton WS; Wissel PS
    Clin Cancer Res; 1996 Jan; 2(1):7-12. PubMed ID: 9816083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro.
    Warmann S; Göhring G; Teichmann B; Geerlings H; Fuchs J
    J Pediatr Surg; 2002 Nov; 37(11):1579-84. PubMed ID: 12407543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.
    Ludescher C; Hilbe W; Eisterer W; Preuss E; Huber C; Gotwald M; Hofmann J; Thaler J
    J Natl Cancer Inst; 1993 Nov; 85(21):1751-8. PubMed ID: 8105101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
    van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
    Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of P glycoprotein activity on normal and leukemic CD34+ cells.
    Drenou B; Fardel O; Amiot L; Fauchet R
    Leuk Res; 1993 Dec; 17(12):1031-5. PubMed ID: 7504150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML.
    Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
    Adv Exp Med Biol; 1999; 457():161-75. PubMed ID: 10500791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.